Skip to Content

Hydrochlorothiazide / triamterene Pregnancy and Breastfeeding Warnings

Hydrochlorothiazide / triamterene is also known as: Dyazide, Maxzide, Maxzide-25

Hydrochlorothiazide / triamterene Pregnancy Warnings

Animal studies have failed to reveal evidence of teratogenicity or fetal harm. There are no controlled data in human pregnancy. AU TGA pregnancy category C: Drugs which, owing to their pharmacological effects, have caused or may be suspected of causing, harmful effects on the human fetus or neonate without causing malformations. These effects may be reversible. Accompanying texts should be consulted for further details. US FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

This drug should be used during pregnancy only if the benefit outweighs the risk to the fetus. AU TGA pregnancy category: C US FDA pregnancy category: C

See references

Hydrochlorothiazide / triamterene Breastfeeding Warnings

UK: Use should be avoided. AU and US: This drug should not be used unless there are no safer alternatives. Excreted into human milk: Yes (hydrochlorothiazide); Unknown (triamterene) Excreted into animal milk: Yes (triamterene) Comments: Some authorities consider use of this drug acceptable during lactation if required by the mother and assuming a hydrochlorothiazide dose of 50 mg/day or less.

See references

References for pregnancy information

  1. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  2. Cerner Multum, Inc. "Australian Product Information." O 0
  3. "Product Information. Maxzide (hydrochlorothiazide-triamterene)." Lederle Laboratories, Wayne, NJ.

References for breastfeeding information

  1. Cerner Multum, Inc. "Australian Product Information." O 0
  2. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  3. "Product Information. Maxzide (hydrochlorothiazide-triamterene)." Lederle Laboratories, Wayne, NJ.
  4. United States National Library of Medicine "Toxnet. Toxicology Data Network. Available from: URL:" ([cited 2013 -]):

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.